PMID- 27484349
OWN - NLM
STAT- MEDLINE
DCOM- 20170926
LR  - 20221207
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 16
DP  - 2016 Aug 2
TI  - Radiation recall gastritis secondary to combination of gemcitabine and erlotinib 
      in pancreatic cancer and response to PPI - a case report.
PG  - 588
LID - 10.1186/s12885-016-2616-3 [doi]
LID - 588
AB  - BACKGROUND: Radiation recall gastritis is rare but can be induced after 
      concurrent chemoradiation for pancreatic cancer. We report a patient with 
      pancreatic cancer who developed radiation-recall gastritis related to a 
      combination of gemcitabine and erlotinib. CASE PRESENTATION: A 54-year-old female 
      with unresectable pancreatic cancer received gemcitabine in combination with 
      radiation therapy followed by chemotherapy with gemcitabine and erlotinib. After 
      completing 2 cycles of chemotherapy, the patient had epigastric pain, nausea, and 
      vomiting. Abdominal computed tomography (CT) scan revealed diffuse wall 
      thickening of the stomach, and esophagogastroduodenoscopy (EGD) showed multiple 
      gastric ulcers. The patient was treated with proton pump inhibitors (PPI) and was 
      continued on maintenance chemotherapy. Two months later, the patient presented 
      with the similar symptoms and persistent gastric ulcers were observed during 
      subsequent EGD. Nevertheless, the patient's symptom had resolved with PPI 
      therapy. Thus, the patient underwent maintenance chemotherapy with gemcitabine 
      and erlotinib for additional 4 cycles. Eventually, follow-up abdominal CT Scan 
      and EGD at 6 months demonstrated resolution of the gastric ulcers. CONCLUSIONS: 
      Physicians should be aware of the possibility of radiation recall gastritis 
      associated with a combination of gemcitabine and erlotinib. Administration of 
      PPIs may mitigate the adverse effects of gemcitabine and erlotinib in the 
      presence of radiation recall gastritis; however further studies are warranted.
FAU - Choi, Seong Ji
AU  - Choi SJ
AD  - Department of Internal Medicine, Korea University Guro Hospital, Korea University 
      College of Medicine, Seoul, South Korea.
FAU - Kim, Hyo Jung
AU  - Kim HJ
AD  - Division of Gastroenterology, Department of Internal Medicine, Korea University 
      Guro Hospital, Korea University College of Medicine, Seoul, South Korea. 
      hjkimmd@korea.ac.kr.
FAU - Kim, Jae Seon
AU  - Kim JS
AD  - Division of Gastroenterology, Department of Internal Medicine, Korea University 
      Guro Hospital, Korea University College of Medicine, Seoul, South Korea.
FAU - Bak, Young-Tae
AU  - Bak YT
AD  - Division of Gastroenterology, Department of Internal Medicine, Korea University 
      Guro Hospital, Korea University College of Medicine, Seoul, South Korea.
FAU - Kim, Jun Suk
AU  - Kim JS
AD  - Division of Oncology, Department of Internal Medicine, Korea University Guro 
      Hospital, Korea University College of Medicine, Seoul, South Korea.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20160802
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0W860991D6 (Deoxycytidine)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & 
      dosage/therapeutic use
MH  - Chemoradiotherapy/*adverse effects
MH  - Deoxycytidine/administration & dosage/analogs & derivatives/therapeutic use
MH  - Endoscopy, Digestive System
MH  - Erlotinib Hydrochloride/administration & dosage/therapeutic use
MH  - Female
MH  - Gastritis/*diagnostic imaging/etiology
MH  - Humans
MH  - Maintenance Chemotherapy
MH  - Middle Aged
MH  - Pancreatic Neoplasms/*therapy
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
MH  - Gemcitabine
PMC - PMC4971692
OTO - NOTNLM
OT  - Erlotinib
OT  - Gastritis
OT  - Pancreatic cancer
OT  - Radiation recall
OT  - Radiotherapy
EDAT- 2016/08/04 06:00
MHDA- 2017/09/28 06:00
PMCR- 2016/08/02
CRDT- 2016/08/04 06:00
PHST- 2016/01/22 00:00 [received]
PHST- 2016/07/25 00:00 [accepted]
PHST- 2016/08/04 06:00 [entrez]
PHST- 2016/08/04 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
PHST- 2016/08/02 00:00 [pmc-release]
AID - 10.1186/s12885-016-2616-3 [pii]
AID - 2616 [pii]
AID - 10.1186/s12885-016-2616-3 [doi]
PST - epublish
SO  - BMC Cancer. 2016 Aug 2;16:588. doi: 10.1186/s12885-016-2616-3.